▲ +67.40% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Dyne Therapeutics in the last 3 months. The average price target is $34.25, with a high forecast of $47.00 and a low forecast of $27.00. The average price target represents a 67.40% upside from the last price of $20.46.
The current consensus among 5 contributing investment analysts is to buy stock in Dyne Therapeutics.
Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.